Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mecamylamine (Targacept).

Abhay Singh1, Deepak K Das, Michael E Kelley

  • 1Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA. asingh@uvm.edu

Idrugs : the Investigational Drugs Journal
|March 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early radiographic accuracy and intra-operative parameters of patient-specific instrumentation versus conventional technique in knee osteotomies for adolescent deformity correction: A prospective comparative study.

Journal of clinical orthopaedics and trauma·2026
Same author

CRISPR-Cas9-Mediated Gene Editing in Hematological Disorders: Advancing Translational and Clinical Applications.

Cureus·2026
Same author

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact.

Cancer·2026
Same author

Toward a Menstrual-friendly School Environment: A Convergent Parallel Mixed Method Study.

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine·2026
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Targacept is developing a low-dose mecamylamine capsule for neuropsychiatric disorders. This nicotinic acetylcholine antagonist shows potential as a novel therapeutic agent.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Nicotinic acetylcholine receptors play a role in various neuropsychiatric disorders.
  • Mecamylamine is a known nicotinic acetylcholine antagonist.
  • Existing treatments for neuropsychiatric disorders have limitations.

Purpose of the Study:

  • To develop a novel, low-dose liquid gel capsule formulation of mecamylamine.
  • To evaluate the potential of this formulation as a treatment for neuropsychiatric disorders.

Main Methods:

  • Formulation development of mecamylamine into a liquid gel capsule.
  • Preclinical studies to assess efficacy and safety (details not provided in the abstract).

Main Results:

Related Experiment Videos

  • A low-dose liquid gel capsule formulation of mecamylamine has been successfully developed.
  • The formulation demonstrates potential for treating neuropsychiatric conditions (specific results not detailed).

Conclusions:

  • The developed mecamylamine formulation offers a promising new therapeutic option.
  • Further clinical investigation is warranted to confirm its efficacy and safety in patients.